We recently published a list of 10 Stocks With At Least $20 Million In Insider Spending Recently. In this article, we are going to take a look at where Tectonic Therapeutic, Inc. (NASDAQ:TECX) stands against other stocks with at least $20 million in insider spending recently.
As the stock market navigates a complex environment shaped by recent trade policies, mixed economic signals, and new geopolitical circumstances, investors must remain vigilant. While many experts raise concerns about potential increased volatility under Trump, some analysts believe he is the most pro-stock market president in U.S. history.
On Monday, one day before Trump’s 25% tariffs on goods imported from Canada and Mexico into the U.S. were set to take effect, markets declined. The broader market fell 1.8%, marking its biggest one-day drop of the year, while tech stocks saw a 2.6% decline.
“No room left for Mexico or for Canada,” Trump said at the White House on Monday. “The tariffs, you know, they’re all set. They go into effect tomorrow.”
With no certainty about how long these fluctuations will continue, investors seem to be growing more cautious. While it’s difficult to predict what will happen next, some experts believe that the U.S. Federal Reserve might cut interest rates.
Equity strategists in a Reuters poll project that the broader market will finish the year 9% higher than its current level. Morgan Stanley’s Andrew Slimmon suggests that the adoption of AI could lead to a productivity boom, similar to what happened with the Internet in the late 1990s.
Amid market fluctuations and uncertainty, insider trading also comes into focus. Executives and insiders, with their valuable insights into company strategy, plans, and future moves, may have trades worth analyzing. For example, when a CEO or CFO invests their own money in company shares, it can signal strong confidence in the company’s potential.
However, it is important to highlight that both insider buying and selling can be driven by various motives; therefore, these actions should be considered only within a broader context of the company’s fundamentals, industry trends, and market conditions. This is why due diligence is crucial before making any investment. Insider trading activity, along with other relevant factors, can offer valuable insights into a company’s capabilities, helping investors make more informed decisions.
Today, we will focus on stocks that have seen at least $20 million in insider spending recently. For this purpose, we used Insider Monkey’s insider trading stock screener, focusing on stocks where at least one insider purchase over the last three months was valued at $20 million or more. Although the total value of insider purchases during this period may be higher, only those worth $20 million or more were considered in this search. Since there were more than 10 stocks meeting this criterion, we selected the 10 stocks with insider purchases ranging from $20 million to $35 million, choosing those with the highest amounts within this range for further analysis.
Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
For each stock, we provide details on the highest individual purchase, the number of insider purchases between $20 million and $35 million over the last three months and the company’s current market capitalization.
A close-up of a biotechnology machine working on an oncology therapy.
Tectonic Therapeutic, Inc. (NASDAQ:TECX)
Highest Individual Purchase: $33,000,000.00
Number of Purchases Worth Between $20 million and $35 million: 1
Market Capitalization: $466.22 million
Second among 10 stocks with at least $20 million in insider spending over the last three months is Tectonic Therapeutic. This is a biotechnology company engaged in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs).
Leveraging its proprietary technology platform, GEODe, the Watertown, Massachusetts-based company is developing innovative biological therapeutics aimed at harnessing the human body to alter the progression of disease. Tectonic primarily focuses on medical conditions with few or no available treatment options. The company was co-founded by Timothy A. Springer and Andrew C. Kruse from Harvard Medical School.
In January, the company shared positive early results from its Phase 1b clinical trial of TX45, its main product candidate. TX45 is a long-acting Fc-relaxin fusion protein designed to help improve heart and lung function. The results showed that a single intravenous dose of TX45 led to significant improvements in heart and lung function in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF). The treatment was well tolerated, with no serious or severe side effects reported.
On February 5, one insider acquired $33 million worth of Tectonic shares at a price of $50 per share. The purchase was part of the company’s $185 million private placement. The stock has lost 49.30% year-to-date and is now trading at $23.41 per share.
Five analysts have an average “Strong Buy” rating on Tectonic stock, according to data from StockAnalysis. The average 12-month price target is $80.5 per share, representing a 243.87% increase from the latest price.
Overall, TECX ranks 2nd on our list of stocks with at least $20 million in insider spending recently. While we acknowledge the potential of TECX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TECX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. This article is originally published at Insider Monkey.
